Date Filed | Type | Description |
06/08/2023 |
4
| Countouriotis Athena (Director) has filed a Form 4 on IOVANCE BIOTHERAPEUTICS, INC.
Txns:
| Granted 51,955 options to buy
@ $0 |
|
05/26/2023 |
4
| Countouriotis Athena (Director) has filed a Form 4 on Passage BIO, Inc.
Txns:
| Granted 24,000 options to buy
@ $1, valued at
$24k
|
|
08/17/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
06/14/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
05/31/2022 |
4
| Countouriotis Athena (Director) has filed a Form 4 on Passage BIO, Inc.
Txns:
| Granted 24,000 options to buy
@ $1.76, valued at
$42.2k
|
|
02/11/2022 |
4
| Countouriotis Athena (President & CEO) has filed a Form 4 on Turning Point Therapeutics, Inc.
Txns:
| Sold 2,971 shares
@ $36.3, valued at
$107.8k
Granted 62,400 shares
@ $0 Granted 224,640 options to buy
@ $37.68, valued at
$8.5M
|
|
07/01/2021 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
05/28/2021 |
4
| Countouriotis Athena (Director) has filed a Form 4 on Passage BIO, Inc.
Txns:
| Granted 16,918 options to buy
@ $13.83, valued at
$234k
|
|
02/11/2021 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
02/10/2021 |
4
| Countouriotis Athena (President & CEO) has filed a Form 4 on Turning Point Therapeutics, Inc.
Txns:
| Granted 22,617 shares
@ $0 Granted 101,775 options to buy
@ $140.01, valued at
$14.2M
|
|
06/10/2020 |
4
| Countouriotis Athena (Director) has filed a Form 4 on IOVANCE BIOTHERAPEUTICS, INC.
Txns:
| Granted 35,000 options to buy
@ $32.17, valued at
$1.1M
|
|
05/26/2020 |
4
| Countouriotis Athena (President & CEO) has filed a Form 4 on Turning Point Therapeutics, Inc.
Txns:
| Bought 4,166 shares
@ $60, valued at
$250k
|
|
03/25/2020 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
03/03/2020 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
03/02/2020 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
02/27/2020 |
3
| Form 3 - Initial statement of beneficial ownership of securities: |
01/08/2020 |
4
| Countouriotis Athena (President & CEO) has filed a Form 4 on Turning Point Therapeutics, Inc.
Txns:
| Granted 706 shares
@ $31.127, valued at
$22k
Granted 325,000 options to buy
@ $63.33, valued at
$20.6M
|
|
09/11/2019 |
4
| Countouriotis Athena (President & CEO) has filed a Form 4 on Turning Point Therapeutics, Inc.
Txns:
| Bought 10,000 shares
@ $45, valued at
$450k
|
|
06/24/2019 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
06/11/2019 |
4
| Countouriotis Athena (Director) has filed a Form 4 on IOVANCE BIOTHERAPEUTICS, INC.
Txns:
| Granted 35,000 options to buy
@ $19.93, valued at
$697.6k
|
|
06/11/2019 |
3
| Countouriotis Athena (Director) has filed a Form 3 on IOVANCE BIOTHERAPEUTICS, INC. |
04/24/2019 |
4
| Countouriotis Athena (President & CEO) has filed a Form 4 on Turning Point Therapeutics, Inc.
Txns:
| Bought 12,000 shares
@ $18, valued at
$216k
|
|
04/16/2019 |
3
| Form 3 - Initial statement of beneficial ownership of securities: |
02/20/2018 |
4
| Countouriotis Athena (SVP, Chief Medical Officer) has filed a Form 4 on Adverum Biotechnologies, Inc.
Txns:
| Granted 160,000 options to buy
@ $6.4, valued at
$1M
|
|
01/25/2018 |
4
| Countouriotis Athena (Director) has filed a Form 4 on Trovagene, Inc.
Txns:
| Granted 54,322 options
@ $0.3, valued at
$16.3k
|
|
09/20/2017 |
3
| Form 3 - Initial statement of beneficial ownership of securities: |
06/21/2017 |
4
| Form 4 - Statement of changes in beneficial ownership of securities |
06/21/2017 |
3
| Form 3 - Initial statement of beneficial ownership of securities |
02/24/2017 |
4
| Form 4 - Statement of changes in beneficial ownership of securities |
02/06/2017 |
4
| Form 4 - Statement of changes in beneficial ownership of securities |
01/09/2017 |
4
| Form 4 - Statement of changes in beneficial ownership of securities |
07/05/2016 |
4
| Form 4 - Statement of changes in beneficial ownership of securities |
02/04/2016 |
4
| Countouriotis Athena (SVP and Chief Medical Officer) has filed a Form 4 on HALOZYME THERAPEUTICS INC
Txns:
| Granted 125,523 options to buy
@ $8.11, valued at
$1M
Granted 73,983 restricted stock units
@ $0 |
|
01/07/2016 |
4
| Countouriotis Athena (SVP and Chief Medical Officer) has filed a Form 4 on HALOZYME THERAPEUTICS INC
Txns:
| Paid exercise price by delivering 3,257 shares
@ $16.39, valued at
$53.4k
Exercised 7,500 restricted stock units
@ $0 |
|
|